Efforts to support the development of fusidic acid in the United States

Clinical Infectious Diseases

Volumn 52, Issue SUPPL. 7, 2011, Pages

  Fernandes, Prabhavathi ^a,b   Pereira, David ^a  

^a Cempra Pharmaceuticals   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUSIDIC ACID; LINEZOLID;

ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; FUNDING; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; UNITED STATES;

ANTI-BACTERIAL AGENTS; DRUG APPROVAL; DRUG INDUSTRY; FUSIDIC ACID; HUMANS; MARKETING; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PATENTS AS TOPIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 79955750642     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir170     Document Type: Article

References (36)

1. Talbot GH, Bradley J, Edwards JE, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-68. (Pubitemid 43271379)
2. Opar A. Bad bugs need more drugs. Nat Rev 2007; 6:943-4. (Pubitemid 350201781)
3. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacoldnet 2006; 44:915-34. (Pubitemid 41252842)
4. Jarvis LM. The Ketek effect. Chem Eng News 2008; 86:861-2.
5. FDA Anti-Infective Drugs Advisory Committee. Appendix A. FDA briefing package. Ketek (telithromycin) briefing document. Bridgewater, NJ: Aventis Pharma Available at: www.fda.gov/ohrms/ockets/ac/03/briefing/3919B1-02-C- FDA%20Appendix%20A.htm. Accessed September 2010.
6. Verbist L. The antimicrobial activity of fusidic acid. J Antimicrob Chem 1990; 25(Suppl B):1-5. (Pubitemid 20087260)
7. Bryskier A. Fusidic acid. In: Bryskier A, ed. Antimicrobial agents, 1st ed. Washington, DC: ASM Press, 2005; 635-41.
8. Pfaller MA, Castanheira M, Sader HS, Jones RN. Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. Int J Antimicrob Agents 2010; 35:282-7.
9. Anderson JD. Fusidic acid: new opportunities with an old antibiotic. Can Med Assoc J 1980; 122:765-9. (Pubitemid 10147425)
10. Ernst J. Fucidin treatment of chronic staphylococcal osteitis and osteomyelitis. Acta Orthop Scand 1969; 40:677.
11. Hierholzer G, Rehn J, Knothe H, Masterson J. Antibiotic therapy of chronic post-traumatic osteomyelitis. J Bone Joint Surg Br 1974; 56:721-9.
12. Machet L, Puissant A, Vaillant L, et al. Treatment of skin infections with two dosages of fusidic acid (500 mg/day and 1 g/day) compared with pristinamycin 2 g/day: a multicenter randomized study. Nouv Dermatol 1994; 13:520-4. (Pubitemid 24306871)
13. Pahle JA. Experiences with fucidin in the treatment of osteomyelitis. Acta Orthop Scand 1969; 40:675.
14. Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 1999; 12(Suppl 2);S66.
15. Turnidge J. Fusidic acid pharmacology, pharmacokinetics and pharma-codynamics. Int J Antimicrob Agents 1999; 12(Suppl 2):S23-34. (Pubitemid 29406139)
16. th ed. Vol 1. Philadelphia: Churchill Livingstone Elsevier, 2010: 355-8.
17. Howden B, Lindsay G. Dumb and dumber-the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006; 42:394-400. (Pubitemid 43122319)
18. Whitby M. Fusidic acid in the treatment of methicillin-resistant Staph-ylococcus aureus. Int J Antimicrob Agents 1999; 12(Suppl 2):S67-71. (Pubitemid 29406143)
19. Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents 1999; 12:S45-58. (Pubitemid 29406141)
20. Livermore D, Duckworth JD, Stephens P. Fusidic acid use and resistance. Lancet 2002; 360:806.
21. Goncalves J, Thorn P. Fusidic acid and the treatment of patients with skin and soft tissue infections. Eur J Clin Res 1991; 1:91-7.
22. Lautenbach EEG, Robinson RG, Koornhof HJ. Serum and tissue concentrations of sodium fusidate in patients with chronic osteomyelitis and in normal volunteers. S Afr J Surg 1975: 21-32.
23. Nordin P, Mobacken H. A comparison of fusidic acid and floxacillin in the treatment of skin and soft-tissue infection. Eur J Clin Res 1994; 5:97-106.
24. Atkins B, Gottlieb T. Fusidic acid in bone and joint infections. Int J Antimicrob Agents 1999; 12(Suppl 2):S79-93. (Pubitemid 29406145)
25. Carr WD, Wall AR, Georgala-Zervogiani S, et al. Fusidic acid tablets in patients with skin and soft tissue infection: a dose finding study. Eur J Clin Res 1994; 5:87-95.
26. Aboltins CA, Page MA, Buising KL, et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007; 13:586-91. (Pubitemid 46730664)
27. Rieutord A, Bourget P, Troche G, Zazzo JF. In vitro study of the protein binding of fusidic acid: a contribution to the comprehension of its pharmacokinetic behavior. Intern J Pharmaceut 1995; 119:57-64.
28. O'Neill AJ, Cove JH, Chopra I. Mutation frequencies for resistance to fusidic acid and rifampin in Staphylococcus aureus. J Antimicrob Chemother 2001; 47:647-50. (Pubitemid 32447653)
29. Food and Drug Modernization Act (FDAMA) of 1997. Enacted by US Congress 21 November 1997. Available at: www.fda.gov/downloads/ RegulatoryInformation/ Legislation/FederalFoodDrugandCosmeticAct FDCAct/ SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFD AMAlaw/UCM089145.pdf. Accessed September 2010.
30. Congressional Record. 2007; 153:S5759-824.
31. Kaye K, Anderson DJ, Choi Y, et al. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin Infect Dis 2008; 46:1568-77. (Pubitemid 351706738)
32. Congressional Record. 2008; 154:S9459-9461, S9638, H10170-10176.
33. Craft JC, Moriarty S, Clark K, et al. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid in the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis 2011; 52(Suppl 7);S520-26.
34. Tsuji BT, Okusanya OO, Bullitta JB, et al. Application of pharmaco-kinetic-pharmacodynamic modeling and justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis 2011; 52(Suppl 7);S513-19.
35. Still JG, Clark K, Degenhardt TP, et al. Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects. Clin Infect Dis 2011; 52(Suppl 7):S504-12.
36. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA, Participants in the CDC-Convened Experts' Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/ ncidod/dhqp/ar-mrsa-ca.html. Accessed 3 July 2008.